CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
News|Videos|June 12, 2025 (Updated: September 10, 2025)
Tirabrutinib for the Treatment of Relapsed or Refractory Primary Central Nervous System Lymphoma: Efficacy and Safety From the Phase II PROSPECT Study
Author(s)Lakshmi Nayak, MD
Dr. Lakshmi Nayak presents results from the Phase II PROSPECT study, demonstrating that tirabrutinib monotherapy yields a 66.7% overall response rate and a manageable safety profile in patients with relapsed or refractory primary central nervous system lymphoma, supporting its potential as an effective treatment option in this challenging population.
Advertisement
Advertisement
Related to this article
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Roswell Park Comprehensive Cancer Center unveiled a new and more compact mobile lung cancer screening unit.
The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.
CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.
The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
3
Phase 1 Data Support DAWN-303’s Evaluation of INCB161734 in Frontline KRAS G12D–Mutated PDAC
4
Tumor-Reactive TIL and UMIS Biomarker Predict Response in Metastatic Uveal Melanoma
5